Current therapies for ANCA-associated vasculitis

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 227-240

  Lally, Lindsay ^a   Spiera, Robert ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

biologics; eosinophilic granulomatosis with polyangiitis (Churg Strauss); granulomatosis with polyangiitis (Wegener's); microscopic polyangiitis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; COTRIMOXAZOLE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; ARTICLE; DISEASE SEVERITY; EOSINOPHILIC GRANULOMA; HUMAN; KIDNEY DISEASE; LUNG HEMORRHAGE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PROCEDURES;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIRHEUMATIC AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PLASMA EXCHANGE;

EID: 84921411565     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-011514-023051     Document Type: Article

References (69)

1. Finkielman JD, Lee AS, Hummel AM, et al. 2007. ANCA are detectable in nearly all patients with active severeWegener's granulomatosis. Am. J. Med. 120(7):9-14
2. Sable-Fourtassou R, Cohen P, Mahr A, et al. 2005. Antineutrophil cytoplasmic antibodies in the Churg-Strauss syndrome. Ann. Intern. Med. 143(9):632-38
3. Flossmann O, Berden A, de Groot K, et al. 2011. Long-Term patient survival inANCA-Associated vasculitis. Ann. Rheum. Dis. 70(3):488-94
4. HoffmanGS, Kerr GS, Leavitt RY, et al. 1992. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116(6):488-98
5. de Groot K, Rasmussen N, Bacon PA, et al. 2005. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 52(8):2461-89
6. Stone JH, Merkle PA, Spiera R, et al. 2010. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N. Engl. J. Med. 363(3):221-32
7. Jones RB, Tervaert JW, Hauser T, et al. 2010. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N. Engl. J. Med. 363(3):211-20
8. Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. 2003. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 48(8):2299-309
9. de Groot K, Harper L, Jayne DR, et al. 2009. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized trial. Ann. Intern. Med. 150(10):670-80
10. Harper L, Morgan MD, Walsh M, et al. 2012. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-Associated vasculitis: long-Term follow-up. Ann. Rheum. Dis. 71(6):955-60
11. de Groot K, Adu D, Savage CO, European Vasculitis Study Group (EUVAS). 2001. The value of pulse cyclophosphamide in ANCA-Associated vasculitis: meta-Analysis and critical review. Nephrol. Dial. Transplant. 16(10):2018-27
12. MukhtyarC, Guillevin L, Cid MC, et al. 2009. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68(3):310-17
13. Falagas ME, Manta KG, Betsi GI, Pappas G. 2007. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin. Rheumatol. 26(5):663-70
14. Cupps TR, Edgar LC, Fauci AS. 1982. Suppression of human B lymphocyte function by cyclophosphamide. J. Immunol. 128(6):2453-57
15. Faurschou M, Westman K, Rasmussen N, et al. 2012. Brief report: long-Term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 34(10):3472-77
16. Hogan SL, Falk RJ, Chin H, et al. 2005. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-Associated small-vessel vasculitis. Ann. Intern. Med. 143(9):621-31
17. Walsh M, Flossmann O, Berden A, et al. 2012. Risk factors for relapse of antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 64(2):542-48
18. Pagnoux C, Hogan SL, Chin H, et al. 2008. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-Associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58(9):2908-18
19. Jayne D, Rasmussen N, Andrassy K, et al. 2003. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349(1):36-44
20. Pagnoux C, Mahr A, Hamidou MA, et al. 2008. Azathioprine or methotrexate maintenance for ANCAassociated vasculitis. N. Engl. J. Med. 359(26):2790-803
21. Metzler C, MiehleN, Manger K, et al. 2007. Elevated relapse rate under oralmethotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology 46(7):1087-91
22. Bremer JP1, Ullrich S, Laudien M, et al. 2010. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis. A retrospective uncontrolled study. Clin. Exp. Rheumatol. 28 (1 Suppl. 57):67-71
23. Hiemstra TF, Walsh M, Mahr A, et al. 2010. Mycophenolate mofetil versus azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized controlled trial. JAMA 304(21):2381-88
24. Silva F, SpecksU, Kalra S, et al. 2010. Mycophenolatemofetil for induction andmaintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-A prospective, open-label pilot trial. Clin. J. Am. Soc. Nephrol. 5(3):445-53
25. Han F, Liu G, Zhang X, et al. 2011. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am. J. Nephrol. 33(2):185-92
26. Alba MA, Flores-Suarez LF. 2013. Seven clinical conundrums in the treatment of ANCA-Associated vasculitis. Clin. Exp. Rheumatol. 31(Suppl. 75):74-83
27. Tadema H, Heeringa P, Kallenberg CG. 2011. Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr. Opin. Rheumatol. 23(4):366-71
28. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. 1996. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 335(1):16-20
29. Specks U, Merkle PA, Seo P, et al. 2013. Efficacy of remission-induction regimens for ANCA-Associated vasculitis. N. Engl. J. Med. 369(5):417-27
30. Cartin-Ceba R, Golbin J, Keogh KA, et al. 2012. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): a single-center ten-year experience. Arthritis Rheum. 64(11):3770-78
31. Smith RM, Jones RB, Guerry M, et al. 2012. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 64(11):3760-69
32. Calich AL, Puechal X, Pugnet G, et al. 2014. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegeners). Results of a single-center cohort study on 66 patients. J. Autoimmun. 50:135-41
33. Wegener's Granulomatosis Etanercept Research Group. 2005. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352(4):351-61
34. Pusey CD, Rees AJ, Evans DJ, et al. 1991. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 40(4):757-63
35. Jayne DR, Gaskin G, Rasmussen N, et al. 2007. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18(7):2180-88
36. Klemmer PJ, Chalermskulrat W, Reif MS, et al. 2003. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney Dis. 42(6)1149-52
37. WalshM, Merkle PA, Peh CA, et al. 2013. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14:73
38. Bayry J, Negi VS, Kayeri SV. 2011. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7(6):349-59
39. Jayne DR, Chapel H, Adu D, et al. 2000. Intravenous immunoglobulin for ANCA-Associated systemic vasculitis with persistent disease activity. QJM 93(7):433-39
40. Martinez V, Cohen P, Pagnoux C, et al. 2008. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-Two patients. Arthritis Rheum. 58(1):308-17
41. Richter C, Schnabel A, Csernok E, et al. 1995. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-Associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. 101(1):2-7
42. Aries PM, Hellmich B, GrossWL. 2005. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?. Clin. Rev. Allergy Immunol. 29(3):237-45
43. Perenyei M, Jayne DR, Flobmann O. 2014. Gusperimus: immunological mechanism and clinical applications. Rheumatology 53:1732-41
44. Flossman O, Baslund B, Bruchfeld A, et al. 2009. Deoxyspergualin in relapsing and refractoryWegener's granulomatosis. Ann. Rheum. Dis. 68(7):1125-30
45. Schmitt WH, Birck R, Heinzel PA, et al. 2005. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol.Dial. Transplant. 20(6):1083-92
46. Holle J, Dubrau C, Herlyn K, et al. 2012. Rituximab for refractory granulomatosis with polyangiitis: comparison of efficacy in granulomatous versus vasculitic manifestation. Ann. Rheum. Dis. 71(3):327-33
47. Aries PM, Hellmich B, Voswinkel J, et al. 2006. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 65(7):853-85
48. Seo P, Specks U, Keogh KA. 2008. Efficacy of rituximab in limited Wegener's with refractory granulomatous manifestations. J. Rheum. 35(10):2017-23
49. Martinez DP, Chaudhry A, Jones RB, et al. 2009. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin. Otolaryngol. 34(4):328-35
50. Lally L, Lebovic R, Huang WT, Spiera R. 2014. Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis. Arthritis Care Res. 66:1403-9
51. Xiao H, Schreiber A, Heeringa P, et al. 2007. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170(1):52-64
52. Schreiber A, Xiao H, Jeannette JC, et al. 2009. C5a receptor mediates neutrophil activation and ANCAinduced glomerulonephritis. J. Am. Soc. Nephrol. 20:289-98
53. Yuan J, Gou SJ, Huang J. 2012. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-Associated vasculitis. Arthritis Res. Ther. 14(3):R140-52
54. Xiao H, Dairaghi DJ, Powers JP, et al. 2014. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25(2):225-31
55. Berden AE, Jones RB, Erasmus DD, et al. 2012. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody associated glomerulonephritis after rituximab therapy. J. Am. Soc. Nephrol. 23(2):313-21
56. Wilde B, Thewissen M, Deamoiseaux J, et al. 2010. T cells in ANCA-Associated vasculitis:What can we learn from lesional versus circulating T cells?. Arthritis Res. Ther. 12(1):204-13
57. McKinney EF, Lyons PA, Carr EJ. 2010. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16(5):586-91
58. Langford CA, Monarch PA, Specks U, et al. 2013. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann. Rheum. Dis. 73(7):1376-9
59. Walsh M, Chaudhry A, Jayne D. 2008. Long-Term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-IH). Ann. Rheum. Dis. 67(9):1322-27
60. ComarmondC, Pagnoux C, Khellaf M, et al. 2013. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-Term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65(1):270-81
61. Sinico RA, Di Toma L, Maggiore U, et al. 2005. Renal involvement in Churg-Strauss syndrome. Am. J. Kidney Dis. 47(5):770-79
62. Guillevin L, Lhote F, GayraudM, et al. 1996. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 75(1):17-28
63. Guillevin L, Pagnoux C, Seror R, et al. 2011. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90(1):19-27
64. Ribi C, Cohen P, Pagnoux C, et al. 2008. Treatment of Churg-Strauss syndrome without poor-prognosis factors: amulticenter, prospective, randomized, open-label study of seventy-Two patients. Arthritis Rheum. 58(2):586-94
65. Gayraud M, Guillevin L, le Toumelin P, et al. 2001. Long-Term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 44(3):666-75
66. Thiel J, H'assler F, SalzerU, et al. 2013. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res. Ther. 15(5):R133-42
67. Jakiela B, Szczeklik W, Plutecka H, et al. 2012. Increased production of IL-5 and dominant Th2-Type response in airways of Churg-Strauss syndrome patients. Rheumatology 51(10):1887-93
68. Kim S, Marigowda G, Oren E, et al. 2010. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J. Allergy Clin. Immunol. 125(6):1336-43
69. Moosig F, GrossWL, HermannK, et al. 2011. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann. Intern. Med. 155(5):341-34